Back to Search
Start Over
A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
- Source :
-
Acta Oncologica . Feb2023, Vol. 62 Issue 2, p126-133. 8p. 1 Diagram, 2 Charts, 1 Graph. - Publication Year :
- 2023
-
Abstract
- Current guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab and a chemotherapeutic agent for 3rd line or later treatments. This study aims to describe the treatment of HER2-positive mBC in 3rd line or later after previous treatment with T-DM1 for mBC in a real-world setting. This observational population-based study included all women diagnosed with HER2-positive mBC in Denmark, previously treated with T-DM1 in the metastatic setting. Patients were included on the date of progression leading to initiation of 3rd line treatment if the patient had received T-DM1 in 1st or 2nd line. If the patient received T-DM1 in 3rd line or later the inclusion was based on the date of progression on T-DM1. The primary end points were overall survival (OS) and progression-free survival (PFS). The study included 272 women with a mean age of 59 (27–86) and a median of 3 (2–11) treatment lines prior to inclusion. At index, all patients had received T-DM1 and 167 (62%) patients had received pertuzumab in the metastatic setting. During follow-up 183 patients received chemotherapy. Of these patients, 120 received chemotherapy combined with trastuzumab, 50 received chemotherapy combined with other HER2-targeted therapy, and 13 received chemotherapy as monotherapy. The remaining 89 patients received either HER2-targeted monotherapy (41), endocrine therapy (31), experimental treatment (10), or no treatment (7). Median PFS was 5.5 months (95% CI, 4.8–6.5) and median OS was 18.5 months (95% CI, 16.2–21.3). In this real-world study, we found that patients were treated with a wide variety of anti-cancer agents with modest efficacy. However, patients in this study did not have access to newer therapies like tucatinib and T-DXd. [ABSTRACT FROM AUTHOR]
- Subjects :
- *THERAPEUTIC use of antineoplastic agents
*SCIENTIFIC observation
*CONFIDENCE intervals
*EPIDERMAL growth factor receptors
*TRASTUZUMAB
*METASTASIS
*TREATMENT effectiveness
*COMPARATIVE studies
*SECONDARY primary cancer
*RESEARCH funding
*POPULATION-based case control
*SURVIVAL analysis (Biometry)
*DESCRIPTIVE statistics
*BREAST tumors
Subjects
Details
- Language :
- English
- ISSN :
- 0284186X
- Volume :
- 62
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Acta Oncologica
- Publication Type :
- Academic Journal
- Accession number :
- 162840794
- Full Text :
- https://doi.org/10.1080/0284186X.2023.2176257